• Ertugliflozin (PF-04971729): Advanced Diabetes Research Work

  2026-05-28

  Ertugliflozin (PF-04971729) empowers researchers with unmatched SGLT2 selectivity and protocol flexibility for diabetes and cardiometabolic studies. This guide translates recent cardiovascular and mechanistic findings into actionable workflows, troubleshooting strategies, and cross-domain research insights.

• Phosbind Acrylamide: Accelerating Protein Phosphorylation An

  2026-05-27

  Phosbind Acrylamide enables precise, antibody-free detection of protein phosphorylation states via SDS-PAGE, streamlining workflows for signal transduction and kinase activity studies. Its unique phosphate-binding mechanism empowers researchers to resolve phosphorylated isoforms efficiently, as demonstrated in advanced plant signaling research and translational studies.

• Dutasteride as a Dual 5-Alpha-Reductase Inhibitor in Prostat

  2026-05-27

  Dutasteride, a potent dual 5-alpha-reductase inhibitor, is pivotal for dissecting androgen-driven mechanisms in prostate cancer and BPH research. This article delivers stepwise experimental protocols, troubleshooting tactics, and cross-study insights to maximize assay reliability, with reference to recent advances in apoptotic pathway modulation and immunometabolic concepts.

• Canagliflozin Hemihydrate: Defining Specificity in Glucose R

  2026-05-26

  Explore the scientific rigor and unique specificity of Canagliflozin hemihydrate in glucose metabolism research. This article delivers in-depth analysis, advanced assay decision-making, and direct insights from cutting-edge mTOR pathway studies.

• A20 Restricts Oxidized Self-DNA Inflammation in Acute Kidney

  2026-05-26

  This study identifies the ubiquitin-editing enzyme A20 as a critical suppressor of oxidized self-DNA-induced inflammation during acute kidney injury (AKI). By uncovering a mechanism in which A20 disrupts NEK7/NLRP3 inflammasome assembly, the results highlight a therapeutic strategy for mitigating AKI progression and sterile inflammation.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Resear

  2026-05-25

  SB 431542 stands out as a selective ALK5 inhibitor, empowering researchers to dissect TGF-β signaling in both cancer immunology and regenerative biology. This article translates advanced findings—like those from cryoablation-mediated immune modulation—into actionable protocols and troubleshooting strategies, maximizing the compound’s reliability for bench-to-impact studies.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-05-25

  This study provides a detailed molecular and epidemiological analysis of carbapenemase-encoding gene (CEG) distribution and transmission in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong, China. The findings reveal the dominance of blaNDM−1 genes, high rates of plasmid-mediated resistance transfer, and multidrug resistance phenotypes, offering critical insights for antimicrobial resistance research and infection control.

• Canagliflozin in Renal Bioenergetics: Beyond Glucose Lowerin

  2026-05-24

  Explore how Canagliflozin, a potent SGLT2 inhibitor, advances diabetes and kidney research by modulating mitochondrial function in proximal tubular cells. This article uniquely details bioenergetic remodeling, practical assay insights, and protocol guidance for investigators.

• Fucoidan in Translational Oncology: Mechanistic Depth and St

  2026-05-23

  This thought-leadership article explores the complex bioactivity of Fucoidan (APExBIO, SKU C4038) as a sulfated α-L-fucan from brown seaweed, emphasizing its multi-pathway anticancer and immune-modulating mechanisms. Drawing on recent mechanistic studies and workflow-driven resources, the article provides actionable guidance for translational researchers seeking to bridge discovery with clinical impact. It highlights protocol parameters for optimal use, assesses the competitive landscape, and articulates a future-facing vision while grounding all claims in credible, cited evidence.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-05-22

  Omeprazole, identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU A2845), is a potent H+,K+-ATPase inhibitor purpose-built for research on gastric acid secretion and antiulcer activity. It should not be used for diagnostic or therapeutic applications, nor substituted for clinical-grade formulations. Its primary utility lies in preclinical, mechanistic, and translational workflows related to gastric acid-related disorders.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-05-22

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for controlled research on gastric acid secretion, antiulcer mechanisms, and peptic ulcer disease models. It should not be used for diagnostic or medical applications; instead, it is best suited to in vitro and in vivo mechanistic studies with rigorous protocol adherence.

• Ferrostatin-1 (Fer-1): Epigenetic Advances in Ferroptosis In

  2026-05-21

  Explore how Ferrostatin-1 (Fer-1) advances ferroptosis assay design by modulating DNA methylation and TET activity. This article reveals unique epigenetic and mechanistic insights for oxidative lipid damage inhibition in disease models.

• Dextrose (D-glucose) in Tumor Immunometabolism & Assay Desig

  2026-05-21

  Dextrose (D-glucose) is the cornerstone for modeling energy metabolism and dissecting hypoxia-driven immunometabolic reprogramming in advanced cellular assays. With exceptional purity and reproducibility, it empowers both foundational and cutting-edge workflows, from cell culture supplementation to tumor microenvironment studies.

• Applied Insights: Ertugliflozin (PF-04971729) in Diabetes Re

  2026-05-20

  Ertugliflozin (PF-04971729) stands out for its exceptional selectivity and translational flexibility in both diabetes and renal glucose transport studies. This article delivers protocol-ready recommendations, comparative workflow analysis, and troubleshooting strategies for maximizing experimental reliability with this SGLT2 inhibitor.

• HyperScript™ Reverse Transcriptase: Precision cDNA Synthesis

  2026-05-20

  Explore how HyperScript™ Reverse Transcriptase advances cDNA synthesis for qPCR and oncology research. This article uniquely connects enzyme design, RNA secondary structure, and translational assay choices, providing a deeper perspective than prior reviews.

15984 records 1/1066 page Next 12345 下5页 Last page